MONTREAL--(BUSINESS WIRE)--My Intelligent Machines (“MIMs”), a leader in artificial intelligence and systems biology, announced it has been granted the 2021 AI Innovation Award by the Association pour le développement de la recherche et l’innovation au Québec (ADRIQ), a Quebec-based research association, during the prestigious Gala that took place virtually on November 25.
Key to its selection in the AI category was the Company’s disruptive innovation at the core of its augmented intelligence software solution, supporting R&D activities and the discovery of therapeutic targets and biomarkers. Of note, this award comes only a few months after MIMs received Anges Quebec’s 2021 Company of the Year Award in recognition of its cutting-edge technologies and its governance.
“Such an award sheds light on MIMs’ exceptional team that develops AI-powered solutions, designed to shift paradigms in the field of therapeutic development in a context of precision medicine”, said Sarah Jenna CO-Founder and CEO of MIMs.
“My Intelligent machines’ team is honoured to be recognized by ADRIQ and excited to grow in such a dynamic, innovative and promising AI ecosystem in Quebec” added Sarah Jenna.
The 2021 Gala also highlighted the performance of thriving companies in various categories such as Partnerships, Industrial Research, Innovation, Life Sciences and Digital Transformation, among others. MIMs warmly congratulates awarded companies and fellow nominees.
Montreal-based My Intelligent Machines (MIMs) is a leader in artificial intelligence and systems biology. MIMs provides Biopharma companies with easy-to-implement and interactive augmented intelligence systems, allowing for accurate biological simulations at early drug development stages, to assist life scientists in the development of precisely targeted and personalized therapies. MIMs continues to expand in the United States and in Europe.
About MIMs’ SaaS solutions
MIMs markets augmented intelligence systems packaged in a software-as-a-service (SaaS) solution, dedicated to empower life scientists. Whereas conventional AI solutions typically operate as a ‘black box’, MIMs software solutions create a synergy between life scientists and the machine, enabling accurate human biology simulations far sooner than late-stage clinical development, thus substantially reducing the significant costs and risks currently incurred. MIMs’ software allows for early-stage patient stratification, endotype characterization, as well as target and biomarker discovery with a precision, never reached before.